Morgan B, Lancaster R, Boyagoda B, Ananda R, Attwood L, Jacka D
BMC Infect Dis. 2024; 24(1):299.
PMID: 38454356
PMC: 10918955.
DOI: 10.1186/s12879-024-09143-0.
Fairbanks C, Peterson C
Front Pain Res (Lausanne). 2023; 4:960389.
PMID: 38028425
PMC: 10646403.
DOI: 10.3389/fpain.2023.960389.
Carlisle V, Maynard O, Bagnall D, Hickman M, Shorrock J, Thomas K
Int J Environ Res Public Health. 2023; 20(2).
PMID: 36674280
PMC: 9865602.
DOI: 10.3390/ijerph20021526.
Nielsen S, Tse W, Larance B
Cochrane Database Syst Rev. 2022; 9:CD011117.
PMID: 36063082
PMC: 9443668.
DOI: 10.1002/14651858.CD011117.pub3.
Ghosh A, Mahintamani T, Rana D, Basu D, Mattoo S
Indian J Psychiatry. 2022; 64(2):199-208.
PMID: 35494328
PMC: 9045353.
DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_792_21.
Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.
Beck L, Parlier-Ahmad A, Martin C
J Subst Abuse Treat. 2021; 132:108506.
PMID: 34098202
PMC: 8630078.
DOI: 10.1016/j.jsat.2021.108506.
Global opioid agonist treatment: a review of clinical practices by country.
Jin H, Marshall B, Degenhardt L, Strang J, Hickman M, Fiellin D
Addiction. 2020; 115(12):2243-2254.
PMID: 32289189
PMC: 7554123.
DOI: 10.1111/add.15087.
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.
Makarenko I, Pykalo I, Springer S, Mazhnaya A, Marcus R, Filippovich S
J Subst Abuse Treat. 2019; 104:34-41.
PMID: 31370983
PMC: 8215516.
DOI: 10.1016/j.jsat.2019.05.008.
Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling.
Zelenev A, Shea P, Mazhnaya A, Meteliuk A, Pykalo I, Marcus R
Int J Drug Policy. 2018; 67:91-101.
PMID: 30503695
PMC: 6537868.
DOI: 10.1016/j.drugpo.2018.09.010.
Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence.
Larance B, Gisev N, Cama E, Nelson E, Darke S, Larney S
Drug Alcohol Depend. 2018; 191:145-151.
PMID: 30107320
PMC: 6698181.
DOI: 10.1016/j.drugalcdep.2018.03.056.
Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058.
Shava E, Lipira L, Beauchamp G, Donnell D, Lockman S, Ruan Y
J Acquir Immune Defic Syndr. 2018; 78(3):300-307.
PMID: 29557855
PMC: 5997518.
DOI: 10.1097/QAI.0000000000001683.
Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S
J Subst Abuse Treat. 2018; 87:1-8.
PMID: 29471921
PMC: 5826566.
DOI: 10.1016/j.jsat.2018.01.007.
Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon.
Ghaddar A, Abbas Z, Haddad R
Harm Reduct J. 2017; 14(1):78.
PMID: 29216892
PMC: 5721516.
DOI: 10.1186/s12954-017-0204-8.
Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
Krawczyk N, Picher C, Feder K, Saloner B
Health Aff (Millwood). 2017; 36(12):2046-2053.
PMID: 29200340
PMC: 6035729.
DOI: 10.1377/hlthaff.2017.0890.
QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings.
Isbister G, Brown A, Gill A, Scott A, Calver L, Dunlop A
Br J Clin Pharmacol. 2017; 83(10):2274-2282.
PMID: 28488266
PMC: 5595951.
DOI: 10.1111/bcp.13326.
In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine.
Mazhnaya A, Bojko M, Marcus R, Filippovych S, Islam Z, Dvoriak S
Drugs (Abingdon Engl). 2016; 23(2):163-175.
PMID: 27458326
PMC: 4957015.
DOI: 10.3109/09687637.2015.1127327.
Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy.
Kutsa O, Marcus R, Bojko M, Zelenev A, Mazhnaya A, Dvoriak S
J Int AIDS Soc. 2016; 19(4 Suppl 3):20897.
PMID: 27435717
PMC: 4951533.
DOI: 10.7448/IAS.19.4.20897.
Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia.
Mukherjee T, Wickersham J, Desai M, Pillai V, Kamarulzaman A, Altice F
Drug Alcohol Depend. 2016; 164:120-127.
PMID: 27207155
PMC: 5592792.
DOI: 10.1016/j.drugalcdep.2016.04.037.
Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist.
Thakarar K, Weinstein Z, Walley A
Postgrad Med J. 2016; 92(1088):356-63.
PMID: 27004476
PMC: 4967553.
DOI: 10.1136/postgradmedj-2015-133720.
Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care.
Lee J, Kresina T, Campopiano M, Lubran R, Clark H
Biomed Res Int. 2015; 2015:137020.
PMID: 25629034
PMC: 4299453.
DOI: 10.1155/2015/137020.